Experts call for Indian pharmaceutical companies to innovate and diversify globally in response to proposed US tariffs on generic medicines, emphasizing patient access.
New Delhi, India Jul 26, 2026 ALN: New Delhi: India's pharmaceutical industry is facing a significant challenge as the proposed US tariffs on imported generic medicines loom on the horizon. Industry leaders and healthcare experts are urging the sector to view these tariffs as a wake-up call to diversify its export markets, accelerate innovation, and ensure that affordable medicines remain accessible to patients globally.
The tariff proposal, announced by US President Donald Trump, outlines a phased framework that will initially maintain zero tariffs on imported generic medicines until August 1, 2028. However, after this period, a steep increase in tariffs is anticipated, with a 100 percent tariff for one year followed by a staggering 200 percent tariff starting August 1, 2029. This move is primarily aimed at encouraging domestic drug manufacturing in the United States, but it has sparked considerable debate within India's pharmaceutical sector regarding its long-term implications.
Nikhil K Masurkar, CEO of ENTOD Pharmaceuticals, has characterized the proposed tariffs not merely as a trade challenge but as an opportunity for long-term strategic transformation. He asserts that the finer details of the tariff proposal remain unclear, but one undeniable fact is that the Indian pharmaceutical industry can no longer afford to be overly reliant on a single export market. "This is the right time to diversify, strengthen the domestic innovation ecosystem, and position India as the healthcare leader of the Global South," Masurkar added, highlighting the importance of proactive measures in response to the shifting global landscape.
Dr. Shefali Mazumdar, a surgeon and eye bank in-charge at Sarojini Naidu Medical College in Agra, emphasized that discussions surrounding trade policies should ultimately focus on patient care. "From a clinician's perspective, the biggest concern is continuity of treatment. Generic medicines allow millions of patients to remain compliant with long-term therapies for chronic diseases because they are affordable," she noted. Dr. Mazumdar expressed concern that if prices rise sharply due to trade barriers, many patients may delay refilling prescriptions, reduce adherence, or discontinue treatment altogether. She pointed out that even in developed healthcare systems, the affordability of medicines directly influences health outcomes. Policies that inadvertently increase medicine costs can lead to higher rates of disease complications, avoidable hospitalizations, and an overall increase in healthcare expenditure.
Vivek Padgaonkar, founder of Paddy Advisory Services LLP and former director of projects and policy at the Organisation of Pharmaceutical Producers of India (OPPI), highlighted the need to strengthen domestic pharmaceutical manufacturing while maintaining the benefits of globally integrated supply chains. He explained that the pharmaceutical industry has evolved through robust international collaboration in research, manufacturing, and supply. "Policies that significantly restrict cross-border movement of medicines could create inefficiencies, increase costs, and reduce the resilience of global healthcare systems," Padgaonkar warned. He advocated for a balanced approach in policy interventions that would strengthen domestic manufacturing while ensuring uninterrupted patient access to safe, effective, and affordable medicines. He argued that collaborative policy frameworks are more likely to yield sustainable healthcare outcomes than measures that create trade barriers.
The experts acknowledged that while the proposed tariffs may prompt companies to reassess their manufacturing strategies over the long term, the process of relocating production facilities is fraught with challenges. Such a transition would require navigating complex regulatory approvals, facilitating technology transfer, developing a skilled workforce, and making substantial investments. These hurdles make it unlikely that relocating production facilities would offer an immediate solution to the impending tariff challenges.
Moreover, the experts emphasized the importance of resilient global supply chains in ensuring uninterrupted access to quality medicines. As healthcare systems worldwide grapple with rising chronic disease burdens and aging populations, the ability to maintain a steady supply of affordable medicines is paramount. The Indian pharmaceutical industry, which is one of the largest suppliers of generic medicines globally, plays a crucial role in this context.
The implications of the proposed US tariffs extend beyond immediate trade concerns; they reflect broader trends in global trade policies and nationalistic approaches to healthcare. As countries increasingly prioritize domestic manufacturing and self-sufficiency, the dynamics of international trade in pharmaceuticals are likely to shift. This shift could lead to a reevaluation of global supply chains, impacting not only the Indian pharmaceutical industry but also the healthcare systems that depend on these medicines.
In light of these developments, industry stakeholders are encouraged to engage in dialogue with policymakers to advocate for frameworks that promote both domestic manufacturing and global collaboration. The goal should be to create an environment where innovation flourishes, and patients continue to have access to affordable treatments, regardless of geopolitical tensions.
The proposed tariffs also highlight a broader trend of protectionism that has been observed in various sectors across the globe. Such policies can disrupt established trade relationships and lead to retaliatory measures from affected countries. If India were to respond with tariffs of its own, it could further escalate trade tensions and complicate the already sensitive dynamics of international trade.
Additionally, the potential for increased tariffs raises questions about the future of bilateral trade agreements between the United States and India. Both countries have been working towards strengthening their ties, and the proposed tariffs could serve as a stumbling block in these efforts. The Indian government, along with industry stakeholders, may need to reassess its strategy in engaging with the US market and explore alternative partnerships with countries that are more open to trade.
Furthermore, the proposed tariffs may also drive innovation within the Indian pharmaceutical sector. Companies may be prompted to invest more in research and development to create new, innovative products that can compete in the global market. This could lead to a shift in focus from generic medicines to more complex formulations and biologics, which could enhance India's position in the global pharmaceutical landscape.
In conclusion, the Indian pharmaceutical industry must remain vigilant and adaptable as it navigates the challenges posed by the proposed US tariffs. The situation serves as a reminder of the complexities of global trade and the need for a multifaceted approach to ensure the sustainability of healthcare systems worldwide. By prioritizing diversification, innovation, and patient access, India can navigate these challenges and continue to be a leader in the global pharmaceutical landscape. The onus is now on industry stakeholders to engage proactively with policymakers, explore new markets, and invest in innovation to safeguard the future of affordable healthcare for millions of patients around the world.
To learn more about the latest developments in Trade & Commerce, stay updated with our exclusive reports and analyses on AiLensNews.
